RUBRYC THERAPEUTICS ENTERS RESEARCH COLLABORATION, LICENCE OPTION AGREEMENT WITH ZAI LABS

KUALA LUMPUR, April 14 -- RubrYc Therapeutics Inc, a pre-clinical biotherapeutics company developing epitope selective therapies, has entered into a research collaboration and licence option agreement with Zai Labs Inc.

This is for the use of RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodies with enhanced biological function for an undisclosed oncology target.

Under the terms of the agreement, RubrYc and Zai Labs will collaborate to identify product candidates using RubrYc’s Discovery Engine, which leverages machine learning and structural data to identify antibodies that bind to subdominant epitopes and exhibit differentiated activity. 

bootstrap slideshow

Upon exercise of the licence option, Zai Labs would have exclusive global rights to develop and commercialise product(s) of the Research Collaboration.

According to a statement, RubrYc will receive an upfront payment and is eligible to receive future research, development and commercialisation milestones on a per candidate basis, along with royalties on world-wide net sales of each product. 

Financial terms of the agreement were not disclosed.

Chief executive officer, Dr. Isaac Bright said: “We are excited that Zai Labs has selected the RubrYc Discovery Engine as part of its efforts to identify biotherapeutics against challenging oncology targets. 

“We look forward to collaborating with Zai Labs to accelerate their research by identifying epitope-specific antibodies with differentiated modes of action. Zai Labs’ oncology expertise complements our interest in bringing novel therapeutics with breakthrough potential to patients in need.”

-- BERNAMA